Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp
(NQ:
LEXX
)
2.690
-0.190 (-6.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in PCG Report Noting Company Could Deliver for Investors
August 17, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System
August 13, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals
August 06, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability
July 29, 2021
Via
CannabisNewsWire
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
July 28, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
July 28, 2021
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Supply Chain
Exposures
Intellectual Property
Supply Chain
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine
July 27, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
July 27, 2021
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives US$3,817,643 From Warrant Exercises
July 26, 2021
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Test Results Boost Lexaria Bioscience Corp. (NASDAQ: LEXX) Potential in Enhancing Antiviral Drugs
July 23, 2021
Via
CannabisNewsWire
Exposures
COVID-19
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward
July 22, 2021
Via
CannabisNewsWire
Topics
Animal Testing
Exposures
Animal Testing
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
July 22, 2021
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Death
Intellectual Property
Exposures
Animal Testing
COVID-19
Death
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine
July 21, 2021
Via
CannabisNewsWire
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
July 21, 2021
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Exposures
Animal Testing
COVID-19
Intellectual Property
CannabisNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’
July 20, 2021
Via
CannabisNewsWire
New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan)
July 16, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
July 15, 2021
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan
July 13, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives Patent Protection in Japan
July 13, 2021
New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes
July 12, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology
July 08, 2021
Via
CannabisNewsWire
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
July 05, 2021
KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces 2021 Annual Meeting Results
June 29, 2021
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 17, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
COVID-19
Product Safety
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 17, 2021
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a...
Via
Newsfile
Exposures
COVID-19
Product Safety
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 15, 2021
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
June 09, 2021
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Exposures
Animal Testing
COVID-19
Intellectual Property
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
June 07, 2021
- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
June 03, 2021
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.